Target intelligence / Profile preview

Kelch-like protein 12 (KLHL12)

Target
KLHL12
Molecular classification
Substrate adaptor protein, BTB (Broad-Complex, Tramtrack and Bric à brac/Pox virus and Zinc finger) domain protein, Kelch domain protein, Component of Cullin-3 ubiquitin ligase complex
01

Overview

KLHL12 encodes a cytoplasmic substrate adaptor protein that is a member of the Kelch-like (KLHL) family, characterized by a BTB/POZ domain, BACK domain, and kelch β-propeller domain. KLHL12 functions as an adaptor for Cullin-3-based E3 ubiquitin ligase complexes, conferring substrate specificity to promote ubiquitination of target proteins such as Dishevelled (DVL), SEC31 (involved in COPII vesicle export), and dopamine D4 receptor. By guiding these ubiquitination events, KLHL12 regulates key pathways including Wnt/β-catenin signaling, critical for cell proliferation, differentiation, and tumorigenesis, and ER-to-Golgi trafficking of collagen, which impacts extracellular matrix synthesis and embryonic development. Mutations or dysregulation have been linked to rare congenital disorders and cancer, while its autoantigenic properties are implicated in autoimmune disease. No clinically approved drugs specifically target KLHL12; however, the protein remains of interest for biomarker discovery and mechanistic studies in oncology and immunology.

Other names
Kelch-like protein 12KLHL12C3IP1DKIRCUL3-interacting protein 1DKIR homologkelch-like protein C3IP1
02

Mechanism of action

Drugs (hypothetical or experimental) would likely act by inhibiting or modulating its adaptor-mediated substrate ubiquitination, potentially altering Wnt signaling or collagen export

03

Biological functions

Protein ubiquitination (adaptor for CUL3 E3 ubiquitin ligase complex)Regulation of Wnt signaling (via Dishevelled ubiquitination)Regulation of ER-Golgi transport and COPII vesicle coat sizeCollagen export and embryonic stem cell divisionSubstrate-specific proteolysis
04

Disease associations

Cancer (modifies Wnt pathway implicated in cancer development)Craniolenticulosutural dysplasiaPrimary biliary cholangitis (as a biomarker)Autoimmune disease (autoantigen in Sjogren’s syndrome)
05

Safety considerations

Systemic inhibition could disrupt essential ubiquitin-mediated processes (such as Wnt signaling and protein export), with risk for developmental and homeostatic perturbation
06

Biomarkers

Primary biliary cholangitis (potential biomarker role)Sjogren’s syndrome (autoantigenic role)

Beyond the preview

Go deeper on Kelch-like protein 12 (KLHL12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kelch-like protein 12 (KLHL12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call